Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients less than or equal to 70 Years Old With Untreated Mantle Cell Lymphoma

Next Previous
Search
Trial Profile

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients less than or equal to 70 Years Old With Untreated Mantle Cell Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; Bendamustine (Primary) ; Cytarabine (Primary) ; Rituximab (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Dec 2024 Planned End Date changed from 31 Mar 2025 to 31 Dec 2025.
    • 10 Dec 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
    • 01 Jul 2023 Results of pooled analysis assessing the safety and tolerability of bendamustine/rituximab plus cytarabine/rituximab, with or without acalabrutinib, in older patients with mantle cell lymphoma from two pilot studies, published in the Clinical Lymphoma, Myeloma & Leukemia.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top